secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069153
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q1 2025: operating loss $12.1M; cash $58M; BDC-4182 Phase 1 open
--------------------------------------------------------------------------------

- Collaboration revenue $1.2M (down from $5.3M in Q1 2024) due to completion of Innovent agreement.
- R&D expense $9.5M (down from $16.5M); G&A $3.8M (down from $5.8M) reflecting May 2024 restructuring.
- Cash balance $58.0M expected to fund operations and milestones through mid-2026.
- BDC-4182 Phase 1 dose-escalation study for gastric/gastroesophageal cancer opened for enrollment in April 2025.
- Partnering process initiated for BDC-3042 after AACR 2025 data showed favorable safety and biological activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017025069153/0000950170-25-069153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017025069153/bolt-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer